NFKB1 and neoplasm: This raises the prospect that elevated CXC-chemokine expression detected in patient serum and/or NF-κB activity in diagnostic biopsy specimens may serve as predictive biomarkers of tumour response to the Hsp90 inhibitors that are used in treating this disease.